Diagnostic performance of Liver FibraChek Dx©, a blood-based test for the non-invasive detection of liver cirrhosis and cancer

doi:10.4254/wjh.v17.i6.106481

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-3)

Sum=3

Jun 27, 2025 (publication date) through Jun 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jun 27, 2025; 17(6): 106481
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.106481

Diagnostic performance of Liver FibraChek Dx^©, a blood-based test for the non-invasive detection of liver cirrhosis and cancer

Fernando Siguencia, Michitaka Matsuda, Vijay Pandyarajan, Sunao Tanaka, Steven M Smith, Catherine Bresee, Ekihiro Seki, Charles J Rosser, Hideki Furuya

Fernando Siguencia, Sunao Tanaka, Steven M Smith, Charles J Rosser, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

Michitaka Matsuda, Vijay Pandyarajan, Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

Catherine Bresee, Department of Biostatistics Shared Resources, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

Ekihiro Seki, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

Hideki Furuya, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

Co-first authors: Fernando Siguencia and Michitaka Matsuda.

Author contributions: Siguencia F and Matsuda M wrote the manuscript; Siguencia F, Matsuda M, Pandyarajan V, Tanaka S, and Smith S performed the research; Matsuda M, Pandyarajan V, Bresee C, and Furuya H analyzed the data and performed investigation, resources; Seki E, Rosser CJ and Furuya H reviewed and edited the manuscript; Rosser CJ and Furuya H designed the research study; all authors have read and agreed to the published version of the manuscript.

Institutional review board statement: This study received approval and a waiver of consent to use previously banked de-identified serum samples from the Cedars-Sinai Medical Center Institutional Review Board, Los Angeles, CA, United States (No. 00002172). Study performance complied with the tenets of the Declaration of Helsinki.

Informed consent statement: This study was conducted using previously banked, de-identified serum samples. The Cedars-Sinai Medical Center Institutional Review Board reviewed the study protocol and granted a waiver of informed consent.

Conflict-of-interest statement: Charles J Rosser is an officer at Nonagen Bioscience Corporation (Los Angeles, CA, United States), which has patent interests in and development rights to the Liver FibraChek Dx^© assay. The remaining authors have no potential conflicts of interest to disclose, financial or otherwise.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Data sharing statement: No additional data are available.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Hideki Furuya, PhD, Associate Professor, Department of Biomedical Science, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, United States. hideki.furuya@cshs.org

Received: February 27, 2025
Revised: April 24, 2025
Accepted: May 29, 2025
Published online: June 27, 2025
Processing time: 118 Days and 19.1 Hours

Core Tip

Core Tip: This retrospective observational study assessed the diagnostic accuracy of Liver FibraChek Dx^©, a non-invasive serum assay for detecting metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). The test algorithm integrates five serum biomarkers and age to produce a risk score. Among 45 participants with biopsy-confirmed diagnoses (MASLD, HCC, or healthy), Liver FibraChek Dx^© achieved an area under the receiver operating characteristic curve of 0.890, with 93.9% sensitivity and 88.9% accuracy. Risk scores significantly distinguished individuals with liver disease from healthy controls. These findings support the potential clinical utility of Liver FibraChek Dx^© in diagnosing and monitoring liver pathogenesis via blood-based testing.